Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Type 2 Diabetes - Pipeline Review, H2 2013 market report to its offering
Type 2 Diabetes - Pipeline Review, H2 2013
, 'Type 2 Diabetes - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 2 Diabetes. Type 2 Diabetes - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Type 2 Diabetes.
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Type 2 Diabetes pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
Eli Lilly and Company
Isis Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Novo Nordisk A/S
Generex Biotechnology Corporation
Takeda Pharmaceutical Company Limited
Piramal Healthcare Limited
Nycomed International Management GmbH
Neurocrine Biosciences, Inc.
Teijin Pharma Limited
Astellas Pharma Inc.
Chong Kun Dang Pharmaceutical
Chugai Pharmaceutical Co. Ltd
Dong-A Pharmaceutical Co., Ltd.
Forest Laboratories, Inc.
Glenmark Pharmaceuticals Ltd.
Ildong Pharmaceutical Co., Ltd.
Japan Tobacco Inc.
Kissei Pharmaceutical Co., Ltd.
Les Laboratoires Servier
Mitsubishi Tanabe Pharma Corporation
Ranbaxy Laboratories Limited
Zydus Cadila Healthcare Limited
Hadasit Medical Research Services & Development Ltd
Zosano Pharma, Inc.
GW Pharmaceuticals plc
Hollis-Eden Pharmaceuticals, Inc.
Enzo Biochem, Inc.
Ligand Pharmaceuticals Incorporated
PROLOR Biotech, Inc.
Oramed Pharmaceuticals, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
ConjuChem Biotechnologies Inc.
Lexicon Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Flamel Technologies S.A.
SANWA KAGAKU KENKYUSHO CO.,LTD.
IPCA Laboratories Limited
LG Life Sciences, Ltd
Transition Therapeutics Inc.
SemBiosys Genetics Inc.
Uni-Bio Science Group Ltd.
Panacea Biotec Limited
Summit Corporation plc
Phynova Group Ltd
NeuroVive Pharmaceutical AB
Advinus Therapeutics Pvt. Ltd.
Chipscreen Biosciences Ltd
Sirtris Pharmaceuticals, Inc.
Celon Pharma Sp. z o.o.
Cortendo Invest AB
Arisaph Pharmaceuticals, Inc.
Metabolic Solutions Development Co.
Catabasis Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc.
Five Prime Therapeutics, Inc.
Melior Discovery, Inc.
Braasch Biotech LLC
Intarcia Therapeutics, Inc.
Kainos Medicine, Inc.
Nordic Bioscience a/s
NOXXON Pharma AG
Avaxia Biologics, Inc.
Janssen Pharmaceutica, Inc.
Intercept Pharmaceuticals, Inc.
Transtech Pharma, Inc.
BRIDGE BIORESEARCH PLC
N-Gene Research Laboratories, Inc.
Obio Pharmaceutical Holdings Limited.
Verva Pharmaceuticals Limited
Medestea Research & Production S.p.A.
Stelic Institute & Co.
Regulus Therapeutics Inc.
Esperion Therapeutics, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
NGM Biopharmaceuticals, Inc.
The Alize Pharma Group
Heptares Therapeutics Ltd.
MicroDose Therapeutx, Inc.
Sirona Biochem Corp
XBiotech USA, Inc.
Connexios Life Sciences Pvt. Ltd.
Stempeutics Research Private Limited
SignPath Pharma Inc
To view the table of contents for this market research report please visit